Plant Name: Arachis hypogaea
Taxonomic Information:
Plant ID: NPO25426
Plant Latin Name: Arachis hypogaea
Taxonomy Genus: Arachis
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3818
Plant-of-the-World-Online:
318562-2
Used in Medicines:
Country/Region:
Philippines; Indonesia; India; France; United States; Senegal; Thailand; Argentina; Burkina Faso; SpainTraditional Medicine System:
Indian Folk; Ayurveda; SiddhaMedicinal Functions:
Antiseborrheic; Aperient; Demulcent; Emollient; Pectoral
Geographical Distribution:
Brazil; Bangladesh; Liberia; Sudan; Guinea; Nepal; Mongolia; France; Malawi; Ethiopia; Rwanda; Tanzania; Laos; Argentina; Bolivia; Cameroon; Cote d'Ivoire; Ecuador; Benin; Ghana; Belarus; Zambia; Burkina Faso; Togo; Trinidad and Tobago; Zimbabwe; China; Thailand; Iraq; Kazakhstan; Sierra Leone; Spain; Nigeria; Ukraine; Eritrea; Uganda; Gambia; Philippines; Indonesia; Turkmenistan; United States; Sri Lanka; Mauritania; Australia; Gabon; Guinea-Bissau; Mali; Yemen; Russia; Pakistan; Angola; Myanmar; Chad; Mexico; South Africa; India; Uzbekistan; Taiwan; Senegal; Vietnam; Mozambique; Colombia; Burundi; Namibia; Niger; Tajikistan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; PIK3CA; PIK3CB; HSD17B10; NQO2; NOX4; | |
| FLT3; | |
| CA2; CA1; CA12; CA9; CA14; CA4; CA7; | |
| ESR1; | |
| PTGS2; | |
| MMP12; | |
| HIF1A; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.205E-14 | 3.489E-10 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.974E-12 | 8.595E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.204E-07 | 2.622E-04 | CA1, CA12, CA2, CA4, CA7, CA9, ESR1, MMP12, NQO2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.823E-07 | 3.609E-04 | CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.842E-07 | 4.760E-04 | CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.238E-06 | 2.707E-03 | CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 3.685E-06 | 3.849E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.712E-06 | 3.849E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 5.404E-06 | 4.691E-03 | CA2, CA7, ESR1, HIF1A, NOX4, PIK3CA, PIK3CB |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.420E-06 | 5.212E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 7.754E-06 | 5.277E-03 | CYP1A2, CYP1B1, CYP3A4, NQO2 |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 8.611E-06 | 5.682E-03 | CYP1B1, HIF1A, PIK3CA, PIK3CB, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.489E-18 | 1.195E-13 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.299E-17 | 1.403E-15 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 8.039E-07 | 4.341E-05 | PIK3CA, FLT3, PIK3CB, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.815E-06 | 6.533E-05 | CYP1A2, CYP1B1, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 7.758E-06 | 2.095E-04 | PIK3CA, PIK3CB, ESR1, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.252E-05 | 4.787E-04 | PIK3CA, FLT3, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 3.083E-05 | 4.787E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.989E-05 | 5.273E-04 | PIK3CA, FLT3, PIK3CB, PTGS2, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 3.796E-05 | 4.787E-04 | PIK3CA, PIK3CB, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 3.989E-05 | 4.787E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.531E-05 | 5.273E-04 | PIK3CA, PIK3CB, HIF1A, ESR1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.427E-05 | 4.787E-04 | CYP1A2, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 5.054E-05 | 5.273E-04 | PIK3CA, PIK3CB, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 6.559E-05 | 5.273E-04 | PIK3CA, PIK3CB, ESR1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.835E-05 | 5.273E-04 | CYP1A2, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.114E-04 | 8.023E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.692E-04 | 1.141E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 1.795E-04 | 1.141E-03 | PIK3CA, PIK3CB, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 2.310E-04 | 1.313E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.902E-04 | 1.141E-03 | PIK3CA, PIK3CB, HIF1A |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.690E-04 | 2.302E-03 | PIK3CA, LMNA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 6.671E-04 | 3.133E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.716E-03 | 6.177E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.304E-03 | 7.318E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.481E-03 | 5.517E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.234E-03 | 7.318E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 2.099E-03 | 7.311E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.370E-03 | 5.286E-03 | CYP1B1, PTGS2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.264E-03 | 5.054E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 2.518E-03 | 7.402E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.050E-03 | 9.800E-03 | PIK3CA, CYP1B1, PTGS2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 8.351E-04 | 3.758E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.374E-03 | 7.326E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 1.111E-03 | 4.616E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.784E-04 | 3.795E-03 | CYP1A2, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.304E-03 | 7.318E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.895E-03 | 7.445E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.741E-03 | 7.402E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.592E-03 | 7.402E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.895E-03 | 7.445E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 4.083E-03 | 9.800E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.606E-04 | 2.302E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.741E-03 | 7.402E-03 | CA2, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 3.297E-03 | 8.282E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.882E-04 | 1.556E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; FLT3; NQO2; CA9; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; FLT3; HIF1A; PTGS2; PIK3CB; NQO2; CA1; CA9; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; PTGS2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; FLT3; HIF1A; PIK3CB; CA9; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
